These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1482938)

  • 1. Drug delivery optimization through Bayesian networks.
    Bellazzi R
    Proc Annu Symp Comput Appl Med Care; 1992; ():572-8. PubMed ID: 1482938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug delivery optimization through Bayesian networks: an application to erythropoietin therapy in uremic anemia.
    Bellazzi R
    Comput Biomed Res; 1993 Jun; 26(3):274-93. PubMed ID: 8325006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rhEPO treatment of anemia in uremic patients.
    Bommer J; Barth HP; Schwöbel B
    Contrib Nephrol; 1990; 87():59-67. PubMed ID: 2093542
    [No Abstract]   [Full Text] [Related]  

  • 4. Subcutaneous low doses of recombinant human erythropoietin in predialysis patients do not interfere with the progression of renal failure.
    Savica V; Costantino G; Monardo P; Bellinghieri G
    Am J Nephrol; 1995; 15(1):10-4. PubMed ID: 7872358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical modeling of erythropoietin therapy in uremic anemia. Does it improve cost-effectiveness?
    Bellazzi R; Siviero C; Bellazzi R
    Haematologica; 1994; 79(2):154-64. PubMed ID: 8063263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP; Abels RI; McNeill MV; Sullivan DJ
    Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uremic inhibitors of erythropoiesis: a study during treatment with recombinant human erythropoietin.
    Brunati C; Cappellini MD; De Feo T; Guastoni C; Ballerini L; Busnach G; Civati G; Fiorelli G; Minetti L
    Am J Nephrol; 1992; 12(1-2):9-13. PubMed ID: 1415372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A therapeutical approach by administering reduced glutathione to patients with uremic anemia].
    Xia N; Qu S
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Jun; 32(2):300-2. PubMed ID: 12600115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacodynamic model of erythropoietin therapy for uremic anemia.
    Uehlinger DE; Gotch FA; Sheiner LB
    Clin Pharmacol Ther; 1992 Jan; 51(1):76-89. PubMed ID: 1732079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
    Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
    Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
    Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
    Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients.
    Buemi M; Allegra A; Laganà A; Aloisi C; Privitera M; Morabito N; Frisina N
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):195-7. PubMed ID: 7761669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin therapy in chronic uremia: the impact of normalization of hematocrit.
    Murphy ST; Parfrey PS
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):573-8. PubMed ID: 10541220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-Carnitine effects on anemia in uremic rats treated with erythropoietin.
    Azzadin A; Wollny T; Pawlak R; Malyszko JS; Malyszko J; Myśliwiec M; Buczko W
    Nephron; 1999; 83(4):370-1. PubMed ID: 10575305
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease.
    Bommer J; Kugel M; Schoeppe W; Brunkhorst R; Samtleben W; Bramsiepe P; Scigalla P
    Contrib Nephrol; 1988; 66():85-93. PubMed ID: 3292151
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease.
    Salvarani C; Lasagni D; Casali B; Macchioni P; Boiardi L; Rossi F; Rivasi P; Portioli I
    J Rheumatol; 1991 Aug; 18(8):1168-71. PubMed ID: 1941817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Erythropoietin: its biological properties and clinical use].
    Ermolenko VM; Nikolaev AIu
    Ter Arkh; 1990; 62(11):141-5. PubMed ID: 2094979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.